Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label single-arm study of HYML-122 in relapsed or refractory FLT3-mutated acute myeloid leukemia
CTR20211928Phase 2Active
- Sponsor
- Hefei Cosource Pharmaceutical
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of CHMFL-FLT3-122 in acute myeloid leukemia (AML), sponsored by Hefei Cosource Pharmaceutical. Started Sep 2021; status: active.
02
Drugs
CHMFL-FLT3-122
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on CTR20211928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211928.